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Background: Autoimmune involvement in the pathogenesis of asthma and chronic obstructive pulmo-
nary disease (COPD) has been proposed, and autoantibodies are a hallmark of autoimmunity. This study
aimed to compare the autoantibody proﬁles of asthma and COPD, and the relationship between auto-
antibodies and features of these diseases.
Methods: We recruited 110 asthma patients and 92 COPD patients for a prospective study. Six autoan-
tibody types were evaluated: antinuclear antibody, anti-cytoplasmic antibodies, rheumatoid factor, anti-
cyclic citrullinated peptide antibody, myeloperoxidaseeanti-neutrophil cytoplasmic autoantibody (MPO-
ANCA) and proteinase 3-ANCA. Other clinical data were also recorded concurrently.
Results: An antinuclear antibody titre of 1:160 presented only in asthma but not in COPD (10% vs. 0%,
p ¼ 0.0002). Eosinophil counts in blood were negative predictors of antinuclear antibody in asthma.
Conversely, eosinophil counts in blood and immunoglobulin-E levels of 100 IU/mL were positively
associated with rheumatoid factor in asthma but not in COPD. There was no relationship between
antinuclear antibody or rheumatoid factor and disease severity.
Conclusions: It is possible that asthma tends to involve autoimmunity associated with antinuclear
antibody more frequently than COPD because asthma is the more robust factor for antinuclear antibody
positivity. Antinuclear antibody and rheumatoid factor are associated with eosinophilic responses, but
they do not work as biomarkers for disease severity.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Asthma and chronic obstructive pulmonary disease (COPD) are
common diseases that are characterised by respiratory symptoms
and airﬂow limitation caused by airway inﬂammation.1,2 TheMedicine, Shinko Hospital, 1-
ety of Allergology.
rgology. Production and hosting by Else
, et al., Autoantibody proﬁles
oi.org/10.1016/j.alit.2016.08.0pathogenesis of asthma and COPD is poorly understood. Asthma is
not considered as a single disease, and its heterogeneity has been
increasingly emphasised by cluster analysis classiﬁcation.3,4
Although cigarette smoking is the main risk factor for COPD, most
smokers do not develop COPD,5 and therefore it is likely that factors
other than smoking are necessary for the development of COPD.6,7
Autoimmune involvement in the pathogenesis of both asthma
and COPD has been proposed, and autoantibodies are a hallmark of
autoimmunity.7e10 It was reported that the prevalence of antinu-
clear antibodies (ANAs) was higher in asthma and COPD patientsvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
and their association with blood eosinophils in asthma and COPD,
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sensitivity and Raynaud's phenomenonweremore common among
patients who presented with ANA in asthma.11 In addition, ANA is
more prevalent in non-atopic asthma than atopic asthma, and
autoimmunity has been proposed as a component of the patho-
genesis of non-allergic asthma.15 Thus, autoimmunity may
contribute to the pathophysiology of asthma and COPD, and may
impair pulmonary function.
To the best of our knowledge, it is unclear whether asthma
and COPD have distinct autoantibody proﬁles. In addition, it is
not completely understood what disease parameters are associ-
ated with the presence of autoantibodies. Therefore, an assess-
ment of autoantibody proﬁles may help to better characterise
asthma and COPD. Here, we conducted a prospective study to
compare the autoantibody proﬁles of asthma and COPD and
assess the relationship between autoantibodies and disease
features.
Methods
Study design and patients
We conducted a prospective observational study. One hundred
and ten asthma and 92 COPD outpatients aged 20 years who
were being treated at Shinko Hospital, Kobe, Japan, between July
2015 and March 2016 were recruited. A diagnosis of asthma was
supported by clinical ﬁndings, including patient history and
clinical course (for example, repeated paroxysmal dyspnoea,
wheezing and cough, and a prompt response to anti-asthma
medication), the existence of atopic disposition and environ-
mental antigen-speciﬁc anti-IgE antibodies, the reversibility of
airﬂow obstruction on spirometry and exclusion of other cardio-
pulmonary diseases. A diagnosis of COPDwas based on a history of
smoking, occupational or environmental exposure, and obstruc-
tive lung disease with a forced expiratory volume in 1 s (FEV1)/
forced vital capacity (FVC) < 70%. All patients were stable at the
time of their inclusion, and patients who experienced collagen
vascular diseases, other respiratory diseases or malignancy and
who received daily systemic corticosteroids and/or immunosup-
pressants were excluded. All participants gave written informed
consent and patient anonymity was preserved using methods
approved by the Ethics Committee. The study was approved by the
Institutional Review Board of Shinko Hospital (approval number:
1503).
Blood test
Using blood samples taken from the recruited patients (8 mL per
patient), we evaluated complete blood cell counts, cell differenti-
ation, IgE and levels of six autoantibody types: ANA, anti-
cytoplasmic antibodies, rheumatoid factor (RF), anti-cyclic cit-
rullinated peptide (CCP) antibody, myeloperoxidaseeanti-neutro-
phil cytoplasmic autoantibody (MPO-ANCA) and proteinase 3-
ANCA (PR3-ANCA). Operators were blinded as to the groups they
analysed. ANA levels were evaluated using a Premmune Hep20-
10FANA kit (Euroimmun, Luebeck, Germany). ANA was ﬂuo-
rescently labelled and then visualised under a ﬂuorescence mi-
croscope. The ﬂuorescence pattern of ANA was determined along
with the cytoplasmic ﬂuorescence pattern of anti-cytoplasmic an-
tibodies (technical support was provided by Toshiharu Saito). ANA
titres of 1:160 were considered to indicate ANA-positive sam-
ples.16 RF levels were evaluated using an N-assay TIA RF kit (Nit-
tobo, Tokyo, Japan) and levels >15 U/L were considered to indicate
RF-positive samples. The anti-CCP antibody was evaluated using
the Architect anti-CCP antibody (Abbott Laboratories, Abbott Park,Please cite this article in press as: Tamai K, et al., Autoantibody proﬁles
Allergology International (2016), http://dx.doi.org/10.1016/j.alit.2016.08.0IL, USA), and levels 4.5 U/mL were considered to indicate anti-
CCP-positive samples. MPO-ANCA and PR3-ANCA levels were
examined using an MPO-ANCA test (BS) and a PR3-ANCA test (BS)
(Medical & Biological Laboratories, Nagoya, Japan), respectively,
and a level of3.5 U/mL was considered to indicate MPO-ANCA- or
PR3-ANCA-positive samples. Blood IgE was examined using an
ImmunoCAP Total IgE kit (Phadia, Uppsala, Sweden) and levels of
100 IU/mL were considered to be high levels of IgE, in accordance
with a previous report.17
Questionnaires
All patients completed questionnaires to assess patient de-
mographics and smoking status. We also checked for previous
episodes of respiratory hospitalisation or unscheduled hospital
visits caused by chest symptoms within a year prior to inclusion in
the study, and these were deﬁned as exacerbations of asthma/
COPD <1 year. An asthma control test (ACT) for asthma patients
and a COPD assessment test (CAT) for COPD patients were per-
formed concurrently with the blood test and pulmonary function
tests. The ACT is a validated questionnaire with ﬁve questions,
which is used to assess if a patient has controlled asthma.18 The
ACT scale ranges from 5 (poor control of asthma) to 25 (complete
control of asthma). The CAT is a questionnaire that is designed to
measure the impact of COPD on a person's life.19 The CAT scale
ranges from 0 to 40, with higher scores indicating worse symp-
toms and control.
Pulmonary function tests
Pulmonary function tests were conducted by trained operators,
in accordance with American Thoracic Society/European Respira-
tory Society guidelines,20 using a CHESTAC-8800 system (Chest,
Tokyo, Japan).
Main outcome measures
The primary objective of the analyses was to compare the
prevalence of each autoantibody between asthma and COPD. The
secondary objective was to ﬁnd the predictors of the presence of
each autoantibody in asthma and COPD.
Statistical analyses
Statistical analysis was performed using JMP 9 software (SAS
Institute Inc., Cary, NC, USA). Continuous variables were expressed
as numbers (%), means (standard deviation [SD]) or medians
(interquartile range [IQR]) depending on the distribution. Com-
parisons between asthma and COPD groups were performed using
a Student's t-test, ManneWhitney U test, chi-square test and
Fisher's exact test, as appropriate. The distribution frequency of
ANA titres between asthma and COPD was compared using a chi-
square test. Gender bias in ANA positive patients was analysed
using Fisher's exact test. Predictors of the presence of ANA and RF
were evaluated using a univariate logistic regression analysis, but
other autoantibodies were not evaluated because of statistical
instability owing to their low prevalence. Comparisons of disease
severity including ACT, CAT, exacerbations of asthma/COPD <1 year,
and FEV1% predicted between ANA or RF positive and negative
groups were performed using a ManneWhitney U test and Fisher's
exact test. Eosinophil counts in blood (ECB) between ANA or RF-
positive and negative groups were compared using a Man-
neWhitney U test. A p-value of <0.05 was deemed statistically
signiﬁcant.and their association with blood eosinophils in asthma and COPD,
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Table 2
Prevalence of autoantibodies in asthma and COPD.
Asthma, n ¼ 110 COPD, n ¼ 92 p Value
ANA, n (%) 11 (10) 0 (0) 0.0002
Homogeneous 4 (4) N/A N/A
Speckled 5 (5) N/A N/A
Centromere 2 (2) N/A N/A
Nucleolar 5 (5) N/A N/A
Peripheral 0 (0) N/A N/A
Granular 2 (2) N/A N/A
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Patients
We included 110 asthma and 92 COPD patients in the study. The
clinical characteristics of the patients are shown in Table 1. Age, sex,
bodymass index (BMI), smoking history, ECB, the levels of blood IgE
and pulmonary function were signiﬁcantly (p < 0.05) different
between the asthma and COPD groups.Nuclear membrane 0 (0) N/A N/A
DFS 70 3 (3) N/A N/A
Others 4 (4) N/A N/A
Anti-cytoplasmic
antibodies, n (%)
2 (2) 1 (1) 1.0
RF, n (%) 12 (11) 9 (10) 0.8
Anti-CCP antibody, n (%) 4 (4) 3 (3) 1.0
MPO-ANCA, n (%) 0 (0) 0 (0) N/A
PR3-ANCA, n (%) 0 (0) 0 (0) N/A
COPD, chronic obstructive pulmonary disease; ANA, antinuclear antibodies; N/A, not
available; DFS, dense ﬁne speckled; RF, rheumatoid factor; CCP, cyclic citrullinated
peptide; MPO, myeloperoxidase; ANCA, anti-neutrophil cytoplasmic autoanti-
bodies; PR3, Proteinase 3.Fluorescence patterns could overlap.Autoantibody proﬁles
The autoantibody proﬁles of the groups are shown in Table 2.
ANA was prevalent in the asthma group only and no one demon-
strated an ANA titre of 1:160 in the COPD group (10% vs. 0%,
p ¼ 0.0002). Seventy-six per cent (84/110) of asthma and 87% (80/
92) of COPD patients presented with an ANA titre of <1:40.
Furthermore, 6% (n ¼ 7) of asthma and 8% (n ¼ 7) of COPD patients
presented with an ANA titre of 1:40, and 7% (n ¼ 8) of asthma and
5% (n ¼ 5) of COPD patients presented with an ANA titre of 1:80.
The distribution frequency of ANA titres was signiﬁcantly (p¼ 0.02)
different between the asthma and COPD groups (Fig. 1). There was
no signiﬁcant difference in ANA positivity between females and
males in asthma (9/64 (14%) vs. 2/46 (4%), p ¼ 0.1). Various ﬂuo-
rescence patterns were observed, including homogeneous,
speckled, centromere, nucleolar, granular and dense ﬁne-speckled
70 patterns, in the asthma group. Furthermore, more than two
ﬂuorescence patterns could overlap. Twelve (11%) asthma patients
and nine (10%) COPD patients were positive for RF. The prevalence
of anti-cytoplasmic antibodies and the anti-CCP antibody was low,
and no patient demonstrated the presence of ANCA. In addition, no
patient who was positive for autoantibodies presented with artic-
ular symptoms, dry mouth, dry eye, Raynaud's phenomenon or
other cutaneous lesions suggesting connective tissue diseases.Fig. 1. Distribution frequency of antinuclear antibody titres was signiﬁcantly different
between the asthma and chronic obstructive pulmonary disease groups.Predictors of ANA and RF
High ECB were negative predictors of ANA in asthma (Table 3).
Conversely, high ECB and high levels of IgE were positively asso-
ciated with RF in asthma but not in COPD (Table 4). There was no
relationship between ANA or RF and disease severity, as predicted
using different criteria including the ACT, CAT, exacerbations in <1Table 1
Baseline characteristics.
Asthma, n ¼ 110 COPD, n ¼ 92 p Value
Age, mean (SD), years 65 (14) 73 (9) <0.0001
Female, n (%) 64 (58) 9 (10) <0.0001
BMI, mean (SD), kg/m2 23.8 (4.5) 22.3 (2.9) 0.005
Smoking history
Current smokers, n (%) 14 (13) 18 (20) 0.2
Former smokers, n (%) 49 (45) 72 (78) <0.0001
Pack-years, median (IQR) 5 (0e28) 57 (39e82) <0.0001
ACT, mean (SD) 22 (4) N/A N/A
CAT, mean (SD) N/A 11 (7) N/A
Exacerbations <1 year, n (%) 26 (24) 17 (18) 0.4
Blood test
Eosinophils, mean (SD), % 5.2 (3.5) 3.5 (2.5) <0.0001
IgE, median (IQR), IU/mL 157 (53e492) 95 (24e376) 0.02
Pulmonary function test
FEV1/FVC, % (SD) 70 (15) 52 (12) <0.0001
FEV1, mean (SD), % predicted 80 (22) 62 (23) <0.0001
COPD, chronic obstructive pulmonary disease; SD, standard deviation; IQR, inter-
quartile range; ACT, asthma control test; N/A, not available; CAT, COPD assessment
test; IgE, immunoglobulin-E; FEV1, Forced expiratory volume in 1 s; FVC, Forced vital
capacity.
Table 3
Predictors of antinuclear antibodies in asthma.
OR 95% CI p Value
Age, per year 1.01 0.96e1.06 0.7
Female 3.60 0.87e24.41 0.08
BMI, per kg/m2 0.94 0.78e1.08 0.4
Smoking history, per pack-year 1.01 0.98e1.03 0.5
ACT, per score 1.09 0.93e1.38 0.3
Exacerbations <1 year 1.24 0.26e4.69 0.8
Eosinophils, per % 0.75 0.53e0.97 0.02
IgE 100 IU/mL 0.48 0.13e1.69 0.2
FEV1% predicted, per % 1.01 0.98e1.04 0.5
COPD, chronic obstructive pulmonary disease; OR, odds ratio; CI, conﬁdence in-
terval; BMI, body mass index; ACT, asthma control test; CAT, COPD assessment test;
IgE, immunoglobulin-E; FEV1, forced expiratory volume in 1 s.
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Allergology International (2016), http://dx.doi.org/10.1016/j.alit.2016.08.0year, or FEV1% predicted (Table 5). The ANA-positive group showed
signiﬁcantly lower ECB than the ANA-negative group in asthma
(median, IQR: 2.9%, 1.6%e4.3% vs. 4.4%, 2.7%e7.5%, p ¼ 0.03)
(Fig. 2A). Conversely, the RF-positive group showed signiﬁcantly
higher ECB than the RF-negative group in asthma (median, IQR:
7.3%, 4.4%e10.6% vs. 3.9%, 2.5%e6.5%, p ¼ 0.02) (Fig. 2B).and their association with blood eosinophils in asthma and COPD,
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Table 4
Predictors of rheumatoid factor.
Asthma COPD
OR 95% CI p Value OR 95% CI p Value
Age, per year 1.02 0.97e1.07 0.5 1.00 0.92e1.08 0.9
Female 1.50 0.44e5.92 0.5 1.17 0.06e7.70 0.9
BMI, per kg/m2 0.93 0.79e1.07 0.4 0.86 0.64e1.13 0.3
Smoking history,
per pack-year
1.00 0.97e1.03 0.8 0.99 0.97e1.01 0.4
ACT, per score 1.08 0.93e1.36 0.4 N/A N/A N/A
CAT, per score N/A N/A N/A 0.92 0.80e1.02 0.1
Exacerbations <1
year
0.62 0.09e2.55 0.5 0.52 0.27e3.16 0.5
Eosinophils, per % 1.21 1.03e1.42 0.02 0.98 0.70e1.26 0.9
IgE 100 IU/mL 7.91 1.45e147.43 0.01 4.14 0.94e28.93 0.06
FEV1% predicted,
per %
0.99 0.96e1.02 0.4 1.01 0.97e1.04 0.7
COPD, chronic obstructive pulmonary disease; OR, odds ratio; CI, conﬁdence inter-
val; BMI, body mass index; ACT, asthma control test; N/A, not available; CAT, COPD
assessment test; IgE, immunoglobulin-E; FEV1, forced expiratory volume in 1 s.
Table 5
Relationship between ANA or RF and disease severity.
ANAþ ANA p Value RFþ RF p Value
Asthma (n ¼ 11) (n ¼ 99) (n ¼ 12) (n ¼ 98)
ACT, mean (SD) 23 (3) 21 (4) 0.4 23 (3) 21 (4) 0.4
Exacerbations <1
year, n (%)
3 (27) 23 (23) 0.7 2 (17) 24 (24) 0.7
FEV1, mean (SD),
% predicted
84 (27) 80 (22) 0.6 75 (26) 81 (22) 0.4
COPD (n ¼ 9) (n ¼ 83)
CAT, mean (SD) N/A N/A N/A 8 (6) 11 (7) 0.2
Exacerbations <1
year, n (%)
N/A N/A N/A 1 (11) 16 (19) 1.0
FEV1, mean (SD),
% predicted
N/A N/A N/A 65 (28) 62 (23) 0.8
ANA, antinuclear antibodies; RF, rheumatoid factor; ACT, asthma control test; FEV1,
forced expiratory volume in 1 s; COPD, chronic obstructive pulmonary disease; CAT,
COPD assessment test; N/A, not available.
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The principal results of this study are the followings. (1) An ANA
titre of 1:160 presented only in asthma and not in COPD. (2) ECB
are negative predictors of the presence of ANA in asthma. (3)Fig. 2. (A) Antinuclear antibodies (ANA)-positive group showed signiﬁcantly lower levels o
factor-positive group showed signiﬁcantly higher levels of eosinophils in asthma.
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with RF in asthma but not in COPD. (4) There is no relationship
between ANA or RF and disease severity. (5) The prevalence of anti-
cytoplasmic antibodies and anti-CCP antibody is low, and the
prevalence of ANCA is extremely low. Overall, it is possible that
asthma tends to involve autoimmunity associated with ANA more
frequently than COPD because asthma is the more robust factor for
ANA positivity, and our results concerning ANA and ECB could
indicate a distinct pathogenesis in asthma.
The prevalence of ANA in asthma and COPD has been reported
previously. Szczeklil et al. reported that ANA at a titre of 1:40 was
present in 55% of patients with aspirin-induced asthma, 41% of
those with intrinsic asthma, 39% of those with atopic asthma, and
11% of healthy subjects, with the difference between each group
and the healthy subjects being statistically signiﬁcant.11 Moreover,
Nú~nez et al. showed that the prevalence of an ANA titre of 1:160
was signiﬁcantly higher in COPD patients than in control subjects
(34% vs. 3%, p < 0.01).21 Bonarius et al. also reported that signiﬁ-
cantly more COPD patients than control subjects were positive for
ANA at a titre of 1:80 (44% vs. 22%, p ¼ 0.001).13 In this study, it
was surprising that ANA at a titre of 1:160 was present only in
asthma but not in COPD, despite other authors reporting high titres
of ANA in COPD patients. It is known that female sex correlates to
ANA positivity,22 and thereweremore females in the asthma group.
However, there was no signiﬁcant difference in ANA positivity be-
tween females and males in the asthma group, and hence gender
bias cannot explain our results. Given that patients with Japanese
ethnicity were recruited to our study, we speculate that ethnic
differences may also have played a role.
Autoimmunity has been proposed as a contributory factor in the
pathogenesis of non-allergic asthma15 and our ﬁndings regarding
the inverse relationship between ECB and ANA in asthma are
consistent with this idea. High ECB indicate T helper type 2 (Th2)-
driven inﬂammation in asthma.23 Although it is poorly understood
whether ANA has any pathophysiological signiﬁcance in asthma or
if it is a nonspeciﬁc marker of an ongoing autoimmune response,
one intriguing interpretation of our results is that asthma with
reduced ECB tends to involve autoimmunity, as represented by
ANA, but not Th2-driven eosinophilic inﬂammation.
Several reports have described the association of RF with eo-
sinophils. It has been shown that ECB are signiﬁcantly higher in
asthma patients who are positive for RF than in those who are
negative for RF.24 Moreover, RF levels are correlated with ECB in af eosinophils compared with the ANA-negative group in asthma. (B) The rheumatoid
and their association with blood eosinophils in asthma and COPD,
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RF levels reﬂect the activity of allergic disorders. However, Rintisch
et al. showed that RF-producing congenic rats, which had been
immunised with ovalbumin, and with experimental allergic bron-
chitis developed a signiﬁcantly increased number of eosinophils in
bronchoalveolar lavage ﬂuid as well as increased total IgE in their
blood, compared with controls.26 Therefore, RF itself may
contribute to the eosinophilic inﬂammatory pathway.
Sigari et al. reported that eight (14%) patients with wood-
smoke-induced COPD, four (7%) patients with tobacco-induced
COPD and two (4%) patients from a healthy control group were
positive for the anti-CCP antibody. However, they compared only
the levels of anti-CCP antibody among these groups and it was not
described whether the anti-CCP antibody positivity signiﬁcantly
differed between the COPD and control groups.27 In our study, only
three (3%) COPD patients were positive for the anti-CCP antibody.
Although smoking is considered a risk factor for both rheumatoid
arthritis (RA) and COPD,28,29 it was difﬁcult to conﬁrm an associa-
tion between the presence of the anti-CCP antibody, which is a
useful diagnostic biomarker for RA,30 and COPD status in our study.
In addition, no patient presented with MPO-ANCA or PR3-ANCA in
this study, so ANCA positivity can be considered as extremely rare
in asthma and COPD.
Although ANA proﬁling studies have previously been conducted
for asthma and COPD, our study is unique in several respects. First,
autoantibodies were investigated in a comprehensive fashion by
evaluating ANA, anti-cytoplasmic antibodies, RF, anti-CCP antibody
and ANCA. Second, we included ECB and blood IgE as covariates of
the Th2 response. Third, we compared asthma with COPD because
they are similar in terms of both being obstructive airway diseases
and a higher ANA prevalence has been previously reported in both.
However, we did not evaluate healthy controls and it is unclear
whether the prevalence of each autoantibody is higher in asthma
and COPD groups than in healthy controls. The prevalence of ANA at
a titre of 1:160 accounts for 2.8% of the Japanese general popula-
tion,22 so the 10% ANA positivity in our asthma patients appears to
be higher than that of Japanese healthy controls. In addition, no
patientwhowaspositive for autoantibodies presentedwitharticular
symptoms, dry mouth, dry eye, Raynaud's phenomenon or other
cutaneous lesions suggesting connective tissue diseases. However,
wedid not perform further examination for autoimmune diseases. It
would be required to study whether the autoantibody positive
asthma and COPD patients have developed the autoimmune dis-
eases. Finally, it might have been difﬁcult to detect the relationship
between the presence of autoantibodies and disease severity
because of the small size of this study. In a large epidemiological
study with 3257 healthy participants, it was found that levels of
autoantibodies were inversely correlated with FEV1/FVC and pre-
dicted FEV1%.31 It may be possible to conﬁrm the relationship be-
tween the presence of autoantibodies and worsening lung function
in asthma and COPD if a larger sample of subjects can be recruited.
In conclusion, it is possible that asthma tends to involve auto-
immunity associatedwith ANAmore frequently than COPD because
asthma is the more robust factor for ANA prevalence, compared
with COPD. ANA and RF are associated with eosinophilic responses
in asthma, but they do not function as biomarkers for disease
severity.
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